



## Post Authorisation Assessments

### Rimadyl Cattle 50 mg/ml Solution for Injection Vm 42058/4118

•	April 2024	Deletion of -a non-significant specification parameter in the specification parameters or limits of an excipient. (NI) Deletion of -a non-significant specification parameter in the specification parameters or limits of an excipient. (NI) Deletion of -a non-significant specification parameter in the specification parameters or limits of an excipient. (NI) Deletion of -a non-significant specification parameter in the specification parameters or limits of an excipient. (NI) Deletion of -a non-significant specification parameter in the specification parameters or limits of an excipient. (NI)
•	April 2024	Deletion of a non-significant specification parameter of an active substance. (GB)
•	13 April 2024	Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State. (NI)
•	14 July 2023	Deletion of a non-significant specification parameter in the specification parameters or limits of an excipient. Deletion of a non-significant specification parameter in the specification parameters or limits of an excipient. Deletion of a non-significant specification parameter in the specification parameters or limits of an excipient. Deletion of a non-significant specification parameter in the specification parameters or limits of an excipient. Deletion of a non-significant specification parameter in the specification parameters or limits of an excipient.
•	06 July 2023	Deletion of a non-significant specification parameter of an active substance.
•	06 July 2023	Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State.(GB)
•	08 March 2023	Addition of a secondary packaging site. Addition of a secondary packaging site.
•	03 November 2022	Change in the name of a quality control testing site.

		Deletion of a manufacturing site for the active substance.
•	12 October 2022	Addition of a secondary packaging site of a finished product. Addition of a secondary packaging site of a finished product.
•	03 December 2019	Change in the address of the marketing authorisation holder from: Zoetis UK Limited, 5th Floor, 6 St. Andrew Street, London, EC4A 3AE to: Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP.
•	27 September 2018	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	06 April 2016	A change to the restricted part of the ASMF.
•	01 May 2015	Changes to the QPPV contact details.
•	29 April 2015	Addition of an active substance manufacturer.
•	17 January 2014	Changes to composition of finished product. Changes to the composition of the stopper. Change to pack size of finished product – addition of 100 ml and 250 ml sizes.
•	09 October 2013	Change in the name and address of the Marketing Authorisation Holder in AT, BE, FR, LU only from Pfizer to Zoetis.
•	03 October 2013	Changes to an existing pharmacovigilance system as described in the DDPS.
•	16 August 2013	Change in distributor and MAH from Pfizer Limited to Zoetis UK Limited.
•	22 February 2013	Renewal – Ireland as RMS.
•	9 February 2012	Change in the name of the address of the MAH in Spain only.
•	15 December 2009	Replacement of the manufacturing site of the finished product.
•	13 November 2009	Alignment of specifications of active substance with new Ph. Eur monograph for carprofen for veterinary use.